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Background/Aims
It is generally believed that cholecystokinin (CCK) stimulates colonic motility, although there are controversial reports. It has also 
been suggested that postprandial peptide YY (PYY) release is CCK-dependent. Using a totally isolated, vascularly perfused rat 
colon, we investigated: (1) the roles of CCK and PYY on colonic motility, (2) to determine if CCK modulates PYY release from 
the colon to influence the motility and (3) to clarify whether the action of CCK and PYY on colonic motility is mediated via 
the influence of cholinergic input. 
Methods
An isolated whole rat colon was used. Luminal pressure was monitored via microtip catheter pressure transducers from prox-
imal and distal colon. After a control period, CCK-8 or PYY was administerd intraarterially with or without an anti-PYY serum, 
loxiglumide or atropine at 12, 60 and 240 pM. Each dose was given for a period of 15-minute and the contractile response 
was expressed as % changes over basal. PYY concentration in the portal effluent was determined by radioimmunoassay. 
Results
Exogenous CCK-8 increased colonic motility which paralleled the increase in PYY release in the portal effluent. Exogenous PYY 
also significantly increased colonic motility although it was less potent than CCK. The stimulating effect of CCK-8 was sig-
nificantly inhibited by an anti-PYY serum, and was completely abolished by loxiglumide, and almost completely abolished by 
atropine. 
Conclusions
CCK increases colonic motility via CCK1 receptor and it is mediated partly by PYY. Cholinergic input is required for the increased 
motility by either PYY or CCK.
(J Neurogastroenterol Motil 2011;17:73-81)
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Introduction
Cholecystokinin (CCK) was indentified in 1966 as a 33 ami-
no acid peptide, extracted from porcine intestine.
1 There are 2 
cell types producing CCK: (1) endocrine cells of the small intes-
tine and (2) various neurons in the gastrointestinal tract and cen-
tral nervous system. CCK is a peptide known to act both as a cir-
culating hormone and as a neurotransmitter.
2,3
CCK stimulates gallbladder contraction and pancreatic en-
zyme secretion, and inhibits gastric emptying which facilitates the 
nutrients digestion and absorption from gut. It was reported that 
CCK stimulates colonic motility in vitro
4 as well as in vivo,
5-7 al-
though there have been controversial reports.
8,9
CCK and gastrin comprise a family of gastrointestinal pep-
tides that share an identical carboxyl-terminal pentapeptide se-
quence. Sulfation of the tyrosine (Tyr) residue at position 7 from 
the carboxyl terminus of CCK is critical for biological activity. 
The characteristic CCK-like activity depends on the sulfated Tyr 
residue at the seventh position. If the Tyr residue is not sulfated, 
or if another amino acid residue is present at this location, the 
peptide behaves as a gastrin analogue and loses its CCK-like 
potency.
The biological actions of CCK are mediated by 2 distinct 
receptors, the originally denoted CCK-A (alimentary type) and 
CCK-B (brain type), based on their anatomical location. They are 
now termed CCK1 and CCK2, respectively, because of the evi-
dences indicating overlapping areas of location.
10
Peptide YY (PYY), a 36 amino acid peptide, isolated from 
the porcine duodenum, has been known to be present in endo-
crine cells, pancreas and brain.
11,12 PYY is found mainly in mu-
cosal endocrine cells of the ileum, colon and rectum.
12-14 In rats, 
it was shown to increase colonic motility,
15 whereas it was re-
ported to either increase or decrease small intestinal motility de-
pending on species.
13,16,17 It has been suggested that the release of 
PYY in postprandial state is mediated by CCK, and PYY was 
shown to be released from rat colon when CCK was administered 
intraarterially in an isolated, vascularly perfused rat colon.
18
The major portion of neurons in human small and large in-
testines are cholinergic. A number of cells resembling enteroen-
docrine cells are found in the epithelium of the small and large 
bowels which contain choline acetyltransferase, a marker of chol-
inergic neurons.
19
In the present study, using a totally isolated, vascularly per-
fused rat colon, we investigated: (1) the roles of CCK and PYY 
on colonic motility, (2) to determine if CCK modulates PYY re-
lease from the colon to influence the motility and (3) to clarify 
whether the action of CCK and PYY on colonic motility is medi-
ated via the influence of cholinergic input.
Materials and Methods
Materials
Bovine serum albumin (BSA) and dextran were purchased 
from Sigma Chemical (St. Louis, MO, USA) and atropine sul-
fate from American Reagent (Shirley, NY, USA). Loxiglumide 
was a gift from the Rotta Research Laboratories (Milan, Italy). 
CCK-8 was purchased from Squibb Diagnostics (Princeton, NJ, 
USA) and PYY from Peninsula (Belmont, CA, USA). PYY an-
tiserum was prepared in University of Rochester (Rochester, NY, 
USA) as described previously.
20 Briefly, anti-PYY serum was 
produced in a New Zealand white rabbit by repeated immuniza-
tion with PYY-BSA conjugate. The antiserum is highly specific 
for PYY. Except for a small crossreaction with neuropeptide Y 
(1%) and avian pancreatic polypeptide (0.01%), it did not cross-
react with other unrelated gut peptides at concentration of 70 
ng/mL in the assay tube.
Animal Preparation
All experiments described in this report were approved by 
Animal Care Committee of the Chungbuk National University 
and University of Rochester. The operative procedure was sim-
ilar to that previously described by Cuber et al for the isolated, 
vascularly perfused duodenojejunum
21 and ileum of the rat.
22 
Male Sprague-Dawley rats weighing between 250 and 300 g 
were fasted for 48 hours with free access to tap water before 
surgery. Under anesthesia with intraperitoneal injection of xyla-
zine 10 mg/kg and zolazepam 50 mg/kg, the abdomen was open-
ed by a midline incision. The stomach, spleen and small intestine 
were removed after ligation of the supplying blood vessels. The 
whole colon was freed of its visceral and retroperitoneal fixations. 
A polyethylene cannula (0.58 mm ID, 0.96 OD) was then in-
serted in superior mesenteric artery and another one (1.52 mm 
ID, 1.90 OD) into the portal vein, respectively. The arterial per-
fusion started immediately at a rate of 1.2 mL/min with Krebs 
solution containing 0.1% BSA and 3% dextran. The mixture was 
continuously gassed with 95% O2 and 5% CO2 and warmed at 
37
oC. The preparation was removed approximately 8 cm in le-
ngth and placed in a water bath at 37
oC. A rubber cannula (5.0 Mechanism of CCK on Colonic Motility
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Figure 1. Schematic illustration of system used in an isolated vascu-
larly perfused rat colon. CCK, cholecystokinin; PYY, peptide YY; 
SMA, superior mesenteric artery; PV, portal vein.
mm ID, 6.5 mm OD) was inserted into both ends of the proximal 
and distal colon to drain the luminal secretion. The loop was then 
flushed out once or twice with 10 mL prewarmed 0.15 M NaCl 
gently. Microtip catheter pressure transducers (2 mm diame-
ter, Millar Inst Inc, Houston, TX, USA) were placed in 2.0 cm 
apart through the ends of the proximal and distal colon, separa-
tely (Fig. 1).
Experimental Procedure
Intraluminal pressure was monitored continuously via micro-
tip catheter pressure transducers. The pressure changes were re-
corded with a Hewlett Packard 7754B system (Hewlett Packard 
Co, Palo Alto, CA, USA). From the recording, motility index 
was calculated by multiplying the amplitude by the duration of 
each contractile wave for 5-minute period and expressed as % 
changes over basal period. All records were analyzed by one ob-
server. Portal venous perfusate was collected as 15 minute frac-
tions in ice-chilled glass tubes and frozen at -20
oC for subsequent 
determination of PYY level by the radioimmunoassay method 
described previously.
20
Effect of exogenous cholecystokinin-8 on colonic mo-
tility
After 30-minute basal period, CCK-8 at 12, 60 and 240 pM 
were administered with each dose given for 15 minutes, starting 
with the lowest dose which was increased in stepwise fashion, 
while portal venous effluent was collected and frozen for future 
radioimmunoassay of PYY.
Effect of exogenous peptide YY on colonic motility
After 30-minute basal period, PYY at 12, 60 and 240 pM 
were administered with each dose given for 15 minutes, starting 
with the lowest dose which was increased in stepwise fashion.
Effect of rabbit anti-peptide YY serum, loxiglumide and 
atropine on colonic motility stimulated by cholecysto-
kinin-8
Effect of rabbit anti-peptide YY serum on colonic 
motility stimulated by cholecystokinin-8. The effect of 
CCK-8 at 240 pM was studied under the influence of a rabbit 
anti-PYY serum or a normal rabbit serum, given in 0.3 mL each. 
Portal venous perfusate was collected and frozen for radioim-
munoassay of PYY.
Effect of loxiglumide on colonic motility stimulated 
by cholecystokinin-8. Under the influence of loxiglumide 
(10
-4 M), the effect of CCK-8 at 240 pM on colonic motility was 
studied. Portal venous perfusate was collected and frozen for ra-
dioimmunoassay of PYY.
Effect of atropine on colonic motility stimulated by 
cholecystokinin-8. Under the influence of atropine (10
-5 M), 
the effect of CCK-8 at 240 pM on colonic motility was studied.
Effect of atropine on colonic motility stimulated by 
peptide YY. Under the influence of atropine (10
-5 M), the effect 
of PYY at 240 pM on colonic motility was studied.
Statistical Methods
The data was expressed as mean ± SE. Statistical analysis 
was performed using the SPSS for Windows version 10 (SPSS 
Inc, Chicago, IL, USA). Correlation analysis was used to de-
termine the effect of CCK or PYY on colonic motility according 
to concentration. Wilcoxon rank-sum test was used to evaluate 
the inhibition of each drugs against stimulation of CCK or PYY 
on colonic motility. A P-value of < 0.05 was considered statisti-
cally significant.
Results
Effect of Exogenous Cholecystokinin-8 on Co-
lonic Motility
CCK-8 dose-dependently stimulated the colonic motility. 
Both in the proximal and distal colon, the percentage changes 
over basal motility indices in response to 3 different doses of 
CCK-8 (12, 60 and 240 pM) were significantly increased to 59%
± 20% and 24% ± 6%, 67% ± 26% and 79% ± 28% and 
112% ± 22% and 134% ± 52%, respectively, which were stat-
istically significant (Fig. 2, 9A and 10A). Interestingly, after 
CCK-8 at doses of 12, 60 and 240 pM, integrated PYY release 
(fmol/15 min) from portal effluent was significantly increased Byeong-Seong Ko, et al
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Figure 2. Effect of intraarterial infusion of cholecystokinin-8 (CCK-8)
on the colonic motility. Data were presented as % increases over the basal
period in response to CCK-8 at doses of 12, 60 and 240 pM. Each bar
represents mean ± SE of 7 experiments. *P <0 . 0 5 ,  **P <0 . 0 1  vs 
basal values.
Figure 3. Integrated release of peptide YY found in the potal effluent 
in response to intraarterial infusion of cholecystokinin-8 at doses of 0, 12,
60 and 240 pM. CCK-8, cholecystokinin-8; PYY, peptide YY. Each 
bar represents mean ± SE of 6 experiments. *P < 0.05 vs basal values.
Figure 5. Effect of cholecystokinin-8 (CCK-8) at 240 pM, on the co-
lonic motility under the influence of saline, normal rabbit serum (NRS) 
or rabbit anti-peptide YY serum. PYY, pepdite YY. Each bar represents
mean ± SE of 5-7 experiments. *P <0 . 0 5 ,   **P < 0.01 vs CCK-8 +
NRS.
Figure 4. Effect of intraarterial infusion of peptide YY (PYY) on the
colonic motility. Data were expressed as % increase over basal period in 
response to PYY at doses of 12, 60 and 240 pM. Each bar represents 
mean ± SE of 6 experiments. *P < 0.05 vs basal values.
from 8.0 ± 3.1 to 17.5 ± 5.3, 22.8 ± 5.6 and 22.3 ± 5.1, re-
spectively (Fig. 3). The increase in colonic motility paralleled the 
increase in PYY release from the portal effluent.
Effect of Exogenous Peptide YY on Colonic 
Motility
In the proximal colon, the increases in the motility over basal 
values in response to 3 different doses of PYY (12, 60 and 240 
pM) were 22% ± 7%, 27% ± 7% and 33% ± 11%, respective-
ly, which were statistically significant. In the distal colon, the mo-
tility index over basal values dose-dependently increased to 6% ±
5%, 37% ± 13% and 52% ± 13%, respectively, which were al-
so statistically significant (Fig. 4, 9B and 10B). Thus, PYY sig-
nificantly and dose-dependently increased colonic motility both 
in the proximal and distal colon, although the magnitude of in-
crease achieved by PYY was significantly less potent than that by 
CCK-8 at the doses employed.Mechanism of CCK on Colonic Motility
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Figure 6. Effect of loxiglumide (10
-4 M) and atropine (10
-5 M) on 
cholecystokinin-8 (CCK-8, 240 pM) stimulated colonic motility. Each 
bar represents mean ± SE of 7 experiments. *P < 0.05, **P <0 . 0 1
vs CCK-8 alone.
Figure 8. Effect of atropine (10
-5 M) on peptide YY (PYY, 240 pM)
stimulated colonic motility. Each bar represents mean ± SE of 6 ex-
periments. *P < 0.05 vs PYY alone.
Figure 7. Effect of loxiglumide (10
-4 M) on peptide YY release in 
portal effluent in response to cholecystokinin-8 (CCK-8, 240 pM) in-
fusion. PYY, peptide YY. Each bar represents mean ± SE of 7 ex-
periments. *P < 0.05 vs CCK-8 alone.
Effect of Rabbit Anti-Peptide YY Serum, Lo-
xiglumide and Atropine on Colonic Motility 
Stimulated by Cholecystokinin-8
Effect of rabbit anti-peptide YY serum on colonic mo-
tility stimulated by cholecystokinin-8
The infusion of a rabbit anti-PYY serum resulted in a pro-
found decrease in the motility index both in the proximal and dis-
tal colon (21.9% ± 1.5% and 8.1% ± 5.0%, P < 0.05), whereas 
it was not influenced by a normal rabbit serum (Fig. 5, 9C, 9D, 
10C and 10D). PYY antibody completely abolished the release of 
portal PYY stimulated by CCK-8 (data not shown).
Effect of loxiglumide on colonic motility stimulated by 
cholecystokinin-8
Under 10
-4 M of loxiglumide background, the CCK action 
to stimulate colonic motility was almost completely abolished 
and the representing motility indices were 2.4% ± 2.1% and 
1.5% ± 1.0%, above basal respectively from the proximal colon 
and distal colon (P < 0.05) (Fig. 6, 9E and 10E). PYY release 
in portal perfusate was also decreased by loxiglumide from 22.3
± 5.1 fmol/15 min during CCK alone to 12.0 ± 5.4 fmol/15 
min after pretreatment with loxiglumide (Fig. 7).
Effect of atropine on colonic motility stimulated by 
cholecystokinin-8
After atropine (10
-5 M), the CCK action to stimulate colonic 
motility was almost completely abolished revealing motility in-
dices from the proximal and distal colon; 5.9% ± 3.8% and 6.5%
± 5.4% above basal (proximal colon, P <0 . 0 5 ;  d i s t a l  c o l o n ,  P
< 0.05 vs 240 pM of CCK) (Fig. 6, 9F and 10F).
Effect of atropine on colonic motility stimulated by 
peptide YY
The stimulation by PYY of colonic motility was almost com-
pletely blocked by atropine in the proximal colon and distal colon 
(2.6% ± 2.6% and 8.2% ± 8.2%; P < 0.05) (Fig. 8, 9G and 
10G).
Discussion
The gut endocrine cells are highly sensitive to ischemia and, 
therefore, their preserved ability to secrete hormones suggests 
perfused organ mobility. The isolated perfused rat colon is a use-Byeong-Seong Ko, et al
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Figure 9. Representative traces respon-
se of isolated rat colon to intraarterial in-
fusion of agents in proximal colon. Re-
sponse of rat colon to intraarterial infusion
of cholecystokinin-8 (CCK-8) (A) and 
peptide YY (PYY) (B) in proximal colon. 
The effect of normal rabbit serum (C), 
anti-PYY serum (D), loxiglumide (E) and
atropine (F) on proximal colonic motility 
stimulated by CCK-8. The effect of atro-
pine (G) on proximal colonic motility sti-
mulated by PYY. NRS, normal rabbit
serum.
ful tool for the investigation of colonic endocrine function and 
secretion.
23
CCK was first discovered in 1928 based on the ability of in-
testinal extracts to stimulate gallbladder contraction in dogs, and 
was later identified in 1966 from porcine intestine due to its rec-
ognition as a potent stimulant in pancreatic enzyme secretion.
1
CCK-8 has been reported to stimulate in vitro colonic muscle 
strips,
4,24 and intact colon of canine
25 and human,
6,7 whereas it 
was also reported to inhibit colonic motility in humans.
8,9 In our 
study, the motor activity of isolated vascularly perfused rat colon, 
including both right and left colon, as measured by intraluminal 
pressure changes, was stimulated by exogenous CCK-8.
Loxiglumide is a potent and specific CCK1 receptor antago-
nist which blocks the CCK action on colon, gallbladder, pancreas 
and stomach in both experimental animals and humans.
3,26 Al-
though CCK1 and CCK2 receptors are present both in central 
nervous system and various peripheral organs, the CCK2 receptor 
is predominantly present in central nervous system. In the intes-
tine, as is in most regions of the gastrointestinal tract, CCK re-
ceptors on smooth muscle cells are CCK1 type. It has long been 
known the gastrin and CCK2 receptors to be similar. The CCK1 
receptor has an approximately 1,000-fold greater affinity for CCK Mechanism of CCK on Colonic Motility
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Figure 10. Representative traces respon-
se of isolated rat colon to intraarterial in-
fusion of agents in distal colon. Response
of rat colon to intraarterial infusion of
cholecystokinin-8 (CCK-8) (A) and pep-
tide YY (PYY) (B) in distal colon. The 
effect of normal rabbit serum (C), anti- 
PYY serum (D), loxiglumide (E) and at-
ropine (F) on distal colonic motility sti-
mulated by CCK-8. The effect of atropine
(G) on distal colonic motility stimulated 
by PYY. NRS, normal rabbit serum.
than for gastrin, while the CCK2 receptor has the same high affin-
ity for both CCK and gastrin. CCK1 receptor responds to sul-
fated CCK with a 1,000-fold greater potency than non-sulfated 
CCK. These receptors are characteristically activated by sulfated 
CCK much more potently than by desulfated CCK or sulfated 
and desulfated gastrin, and are blocked by the benzodiazepine 
derivative, L364,718.
26,27 It has long been known that CCK1 re-
ceptor antagonist is able to shorten colonic transit time.
28 On the 
other hand loxiglumide has been shown to interfere with the gas-
trocolonic reflex and ileal motility and is able to selectively slow 
colonic transit time in patients suffering from IBS.
29 In the pres-
ent study, the stimulating effect of CCK-8 was completely abol-
ished by loxiglumide. 
One of the study provided data regarding the distribution of 
CCK1 receptors in human colon by using receptor autoradiogra-
phy, and it was shown that the main target of CCK was the myen-
teric plexus, which predominantly occupied by CCK1 receptors. 
In addition, CCK1 receptors were distributed at a moderate-to- 
low density in the longitudinal muscle, while the circular muscle 
had no CCK1 receptors.
30 These data suggest that CCK affects 
colonic motility by fundamentally 2 different pathways: acting on 
neurons in the myenteric plexus and directly on the smooth mus-Byeong-Seong Ko, et al
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cle cells.
In the ileum of guinea pig, CCK was shown to stimulate local 
neuronal release of acetylcholine at the neuromuscular junction.
31 
Intraarterial CCK-8 was also shown to produce circular muscle 
contraction of the canine proximal colon that is mediated by stim-
ulation of specific CCK receptors which stimulate the release of 
acetylcholine from cholinergic neurons.
25 In one study, motility 
patterns were compared between healthy volunteers and IBS pa-
tients with abdominal pain and frequent defecation or diarrhea. 
The motility index, the frequency of high-amplitude propagating 
complexes, and also the responses to CCK were significantly 
greater in this subset of IBS patients.
32 The effect of CCK were 
profoundly inhibited by both loxiglumide and atropine.
The effect of PYY on the colonic motility depends on species. 
In the guinea pig and cat, PYY was shown to inhibit both small 
intestinal and colonic motility. In the canine, PYY stimulate small 
intestinal motility. In the rat, PYY inhibit small intestinal motility 
and stimulate colonic motility.
13,15-17 In our study, PYY increased 
colonic motility in the proximal and distal colon.
PYY is not confined to distal intestinal endocrine cells in the 
dog but is also an enteric neuropeptide with maximal concen-
trations being present in the intestinal myenteric plexus.
16 It was 
shown to stimulate circular muscle contractions of the isolated 
perfused canine ileum by enhancing acetylcholine release.
33 Elec-
trical stimulation of the vagus nerve in dogs resulted in release of 
PYY. This data suggests that food-stimulated PYY secretion is 
dependent on ganglionic transmission and an atropine-blockable 
postganglionic parasympathetic pathway.
34 The action of PYY 
appears to heavily depend on the local release of acetylcholine. 
This implies that its action is mediated via the release of ace-
tylcholine by PYY or it may require local cholinergic tone.
Postprandial PYY release is CCK dependent in dogs.
35 Plas-
ma PYY increased with fat, but plasma PYY level was lower fol-
lowing CCK receptor antagonist. CCK serves as a foregut signal 
linking fat in the proximal gut with the release of distal gut 
PYY.
36 Release of PYY by fat in the proximal but not distal gut 
depends on an atropine-sensitive cholinergic pathway.
37 When 
proximal gut contact with fats, the PYY is released via an indirect 
mechanism (CCK and cholinergic pathways); whereas in distal 
gut, the PYY is released via a direct mechanism (exposure of 
PYY releasing cells to fat).
36 In our study, the effect of CCK-8 on 
increasing colonic motility is parallel with the increase in PYY re-
lease from colon. Moreover, the PYY has shown to increase co-
lonic motility in proximal and distal colon as well, although it is 
not as potent as CCK-8 at the doses employed. It was of consid-
erable interest to note that the CCK-stimulated colonic motility 
was profoundly inhibited by both the anti-PYY serum, and lox-
iglumide, accompanied by complete or significant inhibition of 
the release of PYY stimulated by CCK. These results suggest 
that CCK-8 induced colonic motility is significantly mediated by 
PYY.
The pancreatic polypeptide (PP) family consists of 3 pep-
tides; PP, PYY and neuropeptide Y. All 3 peptides are found 
both in the central nervous system and in peripheral tissue, and 
they show a characteristic distribution in the digestive tract.
13,38 
The antiserum used in the present study was highly specific for 
PYY except for a small crossreaction with neuropeptide Y (1%), 
and avian PP (0.01%). As described previously, radioimmuno-
assay for PYY that we used was specific for PYY.
20 It should be 
noted that the amount of PYY released after CCK-8 is relatively 
small, but effect of immunoneutralization of PYY on CCK-sti-
mulated colonic motility was profound. This may be attributed to 
a possibility of PYY to exert as a paracrine or neurocrine me-
ssenger. It has been reported that enteric nervous system contains 
large amount of PYY in the dog.
16 Since both neuropeptide Y 
and PP stimulate the colonic motility, it is possible that the effect 
of either 1 of these 2 in small quantity could have been blocked by 
the anti-PYY serum because of its cross reaction within the 2 
peptides.
We conclude that CCK-8 may increase colonic motility via 
CCK1 receptor and its action is partly mediated by PYY with the 
requirement for cholinergic input in increasing the motility by ei-
ther PYY or CCK.
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